{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:53:18Z","timestamp":1787237598677,"version":"build-2736575974"},"reference-count":74,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T00:00:00Z","timestamp":1326326400000},"content-version":"vor","delay-in-days":437,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:p>Enterococci are a common cause of urinary tract infections (UTIs) among hospitalized patients. The rising prevalence of vancomycin\u2010resistant enterococci (VRE) is of particular concern within many institutions because of its association with increased mortality and health care costs, as well as limited treatment options. Clinicians need to differentiate between VRE\u2010associated urinary colonization, asymptomatic bacteriuria, and UTIs in order to determine the need for treatment, optimal therapeutic options, and length of therapy. Unnecessary use of antibiotics in patients simply colonized and not infected with VRE in the urine has become a large problem in both hospitals and long\u2010term care facilities. A PubMed\u2010MEDLINE search was conducted to identify all English\u2010language literature published between January 1975 and March 2010 in order to summarize diagnostic criteria and treatment options for VRE UTIs. Several antimicrobials are discussed, with the specific focus on those with the potential to treat VRE UTIs and susceptibility patterns of VRE from urinary sources: ampicillin, amoxicillin, daptomycin, doxycycline, fosfomycin, imipenem\u2010cilastatin, linezolid, nitrofurantoin, penicillin, piperacillin, quinupristin\u2010dalfopristin, tetracycline, and tigecycline. Recommendations for empiric treatment of enterococcal UTIs and definitive treatment of VRE UTIs, including an evidence\u2010based treatment algorithm, are proposed. Ampicillin generally is considered the drug of choice for ampicillin\u2010susceptible enterococcal UTIs, including VRE. Nitrofurantoin, fosfomycin, and doxycycline have intrinsic activity against enterococci, including VRE, and are possible oral options for VRE cystitis. Linezolid and daptomycin should be reserved for confirmed or suspected upper and\/or bacteremic VRE UTIs among ampicillin\u2010resistant strains. Use of other antimicrobials, such as quinupristin\u2010dalfopristin and tigecycline, should be evaluated on a case\u2010by\u2010case basis due to concerns of toxicity, resistance, and insufficient supportive data. Additional clinical data are needed to determine the optimal management and duration of therapy for VRE UTIs.<\/jats:p>","DOI":"10.1592\/phco.30.11.1136","type":"journal-article","created":{"date-parts":[[2010,10,25]],"date-time":"2010-10-25T14:25:19Z","timestamp":1288016719000},"page":"1136-1149","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Vancomycin\u2010Resistant Enterococcal Urinary Tract Infections"],"prefix":"10.1002","volume":"30","author":[{"given":"Brett H.","family":"Heintz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenana","family":"Halilovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinda L.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.04.013"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/527394"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/593956"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.12.022"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.4.993"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg352"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440210097010"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/427507"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/650482"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0702.010205"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00070-08"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn065"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2007.01.002"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01641-07"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.9.3.448"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.8.4.585"},{"issue":"47","key":"e_1_2_1_18_2","doi-asserted-by":"crossref","DOI":"10.2807\/ese.13.47.19046-en","article-title":"Emergence and spread of vancomycin resistance among enterococci in Europe [online exclusive article]","volume":"13","author":"Werner G.","year":"2008","journal-title":"Euro Surveill"},{"key":"e_1_2_1_19_2","unstructured":"Center for Disease Control and Prevention.Information for the public about VRE 2008. Available fromhttp:www.cdc.govncidoddhqpar_VRE_publicFAQ.html. Accessed April 20 2010."},{"issue":"3","key":"e_1_2_1_20_2","first-page":"iii13","article-title":"Clinical impact of vancomycin\u2010resistant enterococci","volume":"51","author":"Patel R","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-6553(95)90104-3"},{"key":"e_1_2_1_22_2","first-page":"957","volume-title":"Principles and practice of infectious diseases","author":"Sobel JD","year":"2010"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/646509"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.4.686"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1067\/mic.2000.106904"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0891-5520(20)30149-5","article-title":"Diagnosis and treatment of acute urinary tract infections","volume":"1","author":"Johnson JR","year":"1987","journal-title":"Infect Dis Clin North Am"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/520427"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-6553(88)90053-3"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608153350703"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1062-1066.2000"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.15.4.540"},{"key":"e_1_2_1_32_2","first-page":"76","volume-title":"Performance standards for antimicrobial susceptibility testing; 20th informational supplement: Enterococcus species","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.07.010"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00370-X"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.06.016"},{"key":"e_1_2_1_36_2","first-page":"705","volume-title":"Principles and practice of infectious diseases","author":"Amsden GW","year":"2010"},{"key":"e_1_2_1_37_2","volume-title":"Micromedex 2.0 healthcare series: DRUGDEX system\u20142010","author":"Thomson Micromedex","year":"2010"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A085"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/4.6.580"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/0036554021000026985"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00383-1"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443040-00003"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.11.003"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K561"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00247-06"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.7.792"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M085"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019048-200009090-00004"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000153812.64956.EF"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.4.491"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977223364"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.7.2729-2731.2001"},{"key":"e_1_2_1_53_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/jcm.23.3.421-424.1986","article-title":"Tentative interpretive criteria for in vitro antibacterial susceptibility testing with imipenem","volume":"23","author":"Shungu DL","year":"1986","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.10.3810-3811.2001"},{"key":"e_1_2_1_55_2","first-page":"309","volume-title":"Principles and practice of infectious diseases","author":"Chambers HF","year":"2009"},{"key":"e_1_2_1_56_2","unstructured":"Cubist Pharmaceuticals Inc.Cubicin (daptomycin) package insert. Lexington MA; 2010. Available fromhttp:www.cubicin.compdfPrescribingInformation.pdf. Accessed April 20 2010."},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.12.2348"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2006.11.007"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2007.06.009"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.13.2315"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.12.006"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1086\/320185"},{"key":"e_1_2_1_63_2","first-page":"466","article-title":"In vitro activity of nitrofurantoin in Enterococcus urinary tract infection","volume":"54","author":"Butt T.","year":"2004","journal-title":"J Pak Med Assoc"},{"key":"e_1_2_1_64_2","first-page":"55","article-title":"Antimicrobial susceptibility patterns of common and unusual Enterococcus species isolated from clinical specimens","volume":"24","author":"Chaudhary U.","year":"2007","journal-title":"J Infect Dis Antimicrob Agents"},{"key":"e_1_2_1_65_2","first-page":"644","volume-title":"Susceptibility trends of conventional agents for the treatment of vancomycin\u2010resistant enterococcal infection [abstract]. In program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy","author":"Linden P.","year":"1999"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn354"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI103974"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.144"},{"key":"e_1_2_1_69_2","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.42.10.2710","article-title":"Treatment of vancomycin\u2010resistant Enterococcus faecium with RP 59500 (quinupristin\u2010dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations","volume":"42","author":"Aeschlimann JR","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1319-1324.2002"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1086\/505494"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02494-07"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522080-00001"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291808"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1080\/01952307.1992.11735873"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.30.11.1136","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.30.11.1136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:31:05Z","timestamp":1761067865000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.30.11.1136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":74,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1592\/phco.30.11.1136"],"URL":"https:\/\/doi.org\/10.1592\/phco.30.11.1136","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"2012-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}